OSTX files late 10-Q notice for Q1 2026

OS Therapies Incorporated notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the original due date of May 15, 2026 due to additional time needed to complete the financial statement close process.

Rhea-AI Filing Summary

OS Therapies Incorporated notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the original due date of May 15, 2026 due to additional time needed to complete the financial statement close process. The company states it expects to file the Form 10-Q within the five-calendar-day extension provided by Rule 12b-25.

Insights

Corporate Governance Analyst

Late 10-Q filing linked to close-process delays; company seeks standard five-day relief.

The notice states the Form 10-Q for the quarter ended March 31, 2026 could not be filed by the original due date of May 15, 2026 because additional time was required to complete and review the financial statement close process. The company invokes Rule 12b-25 and expects to file within the five-calendar-day extension.

Cash‑flow treatment and material changes in results are not disclosed in the excerpt; subsequent filings will contain the actual Form 10-Q and any accountant statements if applicable. Stakeholders should watch for the filed Form 10-Q and any accompanying auditor communications for definitive financial details.

Key Figures

Period end: March 31, 2026 Original due date: May 15, 2026 Extension period: 5 calendar days +2 more

5 metrics

Period end March 31, 2026 Quarter ended

Original due date May 15, 2026 Form 10-Q prescribed due date

Extension period 5 calendar days Rule 12b-25 relief for Form 10-Q

SEC File Number 001-42195 Filing identifier

Registrant address 115 Pullman Crossing Road, Suite 103 Principal executive office, Grasonville, Maryland

Key Terms

Rule 12b-25, Form 10-Q, financial statement close process

3 terms

Rule 12b-25 regulatory

"expects to file the Form 10-Q within the extension period of five calendar days, as provided under Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"will not be able to file its Quarterly Report on Form 10-Q for its quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

financial statement close process financial

"delays in compiling and reviewing certain information resulting primarily from additional time required to complete the financial statement close process"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OSTX file with the SEC?

OSTX filed a Form 12b-25 notifying the SEC of a late Form 10-Q filing. The notice cites delays in completing the financial statement close process and invokes the five-calendar-day extension under Rule 12b-25.

Which reporting period is affected for OSTX?

The late filing concerns the quarter ended March 31, 2026. The company acknowledges the original Form 10-Q due date of May 15, 2026 and expects to use the five-day extension.

How long does OSTX expect to delay the 10-Q?

OSTX expects to file the Form 10-Q within the five-calendar-day extension provided by Rule 12b-25. The notice explicitly references the five-day extension and explains the delay stems from the financial close process.

Does the notice say the results will change materially?

The notice answers that question with a checked response of No to significant changes from the prior-year period. No quantitative or narrative change in results is included in the excerpt.

Who signed the Form 12b-25 for OSTX?

The Form 12b-25 is signed by Paul Romness, Chief Executive Officer, on behalf of OS Therapies Incorporated, with a signature date of May 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:15 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC File Number: 001-42195

CUSIP Number: 68764Y207

(Check One):	☐   Form 10-K	☐   Form 20-F	☐   Form 11-K	☒   Form 10-Q	☐   Form 10-D
	☐   Form N-CEN	☐   Form N-CSR

For Period Ended: March 31, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended: _____________

Read Instruction (on back page) Before Preparing Form.  Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I

REGISTRANT INFORMATION

OS Therapies Incorporated

Full Name of Registrant

Not Applicable

Former Name if Applicable

115 Pullman Crossing Road, Suite 103

Address of Principal Executive Office (Street and Number)

Grasonville, Maryland 21638

City, State and Zip Code 

PART II
RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

☒	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III

NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

OS Therapies Incorporated (the “Company”) has determined that it will not be able to file its Quarterly Report on Form 10-Q for its quarter ended March 31, 2026 (the “Form 10-Q”) by May 15, 2026, the original due date for such filing, without unreasonable effort or expense, due to delays in compiling and reviewing certain information included in the Form 10-Q resulting primarily from additional time required for the Company to complete the financial statement close process. The Company expects to file the Form 10-Q within the extension period of five calendar days, as provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended.

PART IV

OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Paul Romness		(410)		297-7793
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

☒ Yes     ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes     ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

OS Therapies Incorporated

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 15, 2026	By:	/s/ Paul Romness
		Paul Romness
		Chief Executive Officer

3